SCHEMBL3300762

SCHEMBL3300762

COc1ccc(CNc2nc3c(c(=O)n2-c2cccc(OC)c2)CN(C(=O)Nc2ccc(Cl)cc2Cl)CC3)cc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PRLHR P49683 9/20 0.49
CACNA1G O43497 1/20 0.43
PDE5A O76074 1/20 0.42
TAS1R3 Q7RTX0 2/20 0.42
TAS1R1 Q7RTX1 2/20 0.42
TAS1R2 Q8TE23 2/20 0.42
KMT2A Q03164 3/20 0.41
GAA P10253 2/20 0.41
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 1/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40
CLPP Q16740 1/20 0.38
MEN1 O00255 2/20 0.38
POLB P06746 1/20 0.38
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3300088 0.98 PRLHR (0.50) PRLHRCACNA1GPDE5ATAS1R3TAS1R1
SCHEMBL3299402 0.95 PRLHR (0.48) PRLHRCACNA1GPDE5ATAS1R3TAS1R1
SCHEMBL3300421 0.95 PRLHR (0.50) PRLHRCACNA1GPDE5ATAS1R3TAS1R1
SCHEMBL3304721 0.94 PRLHR (0.47) PRLHRCACNA1GPDE5ATAS1R3TAS1R1
SCHEMBL3297255 0.94 PRLHR (0.52) PRLHRPDE5ATAS1R3TAS1R1TAS1R2
SCHEMBL3297159 0.94 PRLHR (0.48) PRLHRCACNA1GPDE5ATAS1R3TAS1R1
SCHEMBL3304464 0.94 PRLHR (0.53) PRLHRPDE5ATAS1R3TAS1R1TAS1R2
SCHEMBL3295372 0.93 PRLHR (0.48) PRLHRPDE5ATAS1R3TAS1R1TAS1R2
SCHEMBL3299362 0.92 PRLHR (0.45) PRLHRCACNA1GPDE5ATAS1R3TAS1R1
SCHEMBL3298648 0.92 PRLHR (0.47) PRLHRPDE5ATAS1R3TAS1R1TAS1R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232282-B2 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-31 US disclosed
US-20100093771-A1 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-04-15 US disclosed
EP-2078719-A1 COMPOUND HAVING BICYCLIC PYRIMIDINE STRUCTURE AND PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2009-07-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093771-A1 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same GART, MGAT2, MGAT1 PRLHR 3093/4885CACNA1G 1844/4885PDE5A 2992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.